Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Ryght AI tackles these hurdles with its AI Site Twin platform
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Subscribe To Our Newsletter & Stay Updated
